.png){kind=icon}
.png){kind=icon}
Return
T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
.png){kind=icon}
PRE
AI
M
S
M
I
H
L
F
N
J
E
C
R
F
S
M
M
A
T
G
J
DOI：10.1016/j.ctrv.2026.103201.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Various T-cell engagers (TCEs) are in development for small-cell lung cancer (SCLC). • Tarlatamab is a DLL3-targeted TCE approved for use in pretreated SCLC. • Safe and effective implementation of TCE therapy requires: • Effective TCE-related side-effect management. • Multidisciplinary collaboration and patient/caregiver education.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
No organization information available
Cited Papers